Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
UNIVERSITE JEAN MONNET SAINT ETIENNE is managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The prosecution of this portfolio is currently handled by 1 distinct examiner and 1 distinct art unit. This distribution indicates that the company's active patenting efforts are concentrated in a single specialized section of the patent office. This focused approach can lead to a more predictable examination process as the applicant only needs to address the concerns of 1 distinct examiner.
The busiest examiner for the portfolio is MACFARLANE, STACEY NEE, who is assigned 1 pending office action. This 1 pending office action represents the full extent of the company's current pending activity. The involvement of 1 distinct art unit suggests a consistent technical classification for the subject matter under review. For the practitioner, this means that the immediate focus is entirely on the interactions and procedural expectations of MACFARLANE, STACEY NEE within their assigned art unit. Tailoring responses to the specific preferences of this examiner is essential for advancing the 1 pending office action in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MACFARLANE, STACEY NEE | 1 | 53.5% | +39.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17923161 | METHOD FOR DETECTING INFLAMMATION-RELATED PLATELET ACTIVATION | MACFARLANE, STACEY NEE | 17d overdue |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17923161 | METHOD FOR DETECTING INFLAMMATION-RELATED PLATELET ACTIVATION | MACFARLANE, STACEY NEE | 1675 | §103 | Final Rejection | 17d overdue | Pending | Nov 03, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial